What is IGF-1 LR3? What it does, benefits and what the evidence shows

IGF-1 LR3 (long R3 IGF-I) is a laboratory-modified version of insulin-like growth factor 1, engineered to avoid the binding proteins that normally hold IGF-1 in check. It was built as a research tool and is used to feed cells in culture, and it is sold to bodybuilders for muscle growth. It has never been approved for use in people, and we found no human trial of it. What is known about its effects in a living body comes from rats, pigs, guinea pigs and marmosets, and the results are mixed on muscle and consistent on two things buyers should care about: low blood sugar and growth of organs.

What IGF-1 LR3 is and how it works

IGF-1 is the hormone that carries most of growth hormone's growth-promoting effects. In the blood it is mostly locked up by IGF-binding proteins, which control how much reaches tissues. The LR3 version was made in the early 1990s by swapping one amino acid (arginine for the glutamic acid at position 3) and adding a short extension to the front of the chain, made from the first 11 amino acids of porcine growth hormone plus a two-amino-acid linker. In cell tests, this "Long [Arg3]-IGF-I" was more potent than normal IGF-1 in cells that make binding proteins, but less potent in chicken cells that make none (Francis et al., Journal of Molecular Endocrinology, 1992). A companion paper concluded that the extra potency came from reduced binding to the binding proteins, not from grabbing the IGF-1 receptor harder (King et al., Journal of Molecular Endocrinology, 1992); in fact, LR3 binds the type 1 IGF receptor about three times less well than IGF-1 (Tomas et al., Biochemical Journal, 1992).

The "long" in the name refers to that extended chain, not to how long it lasts. In rats, LR3 is cleared from the blood faster than IGF-1, precisely because it is not held by binding proteins (Bastian et al., Journal of Endocrinology, 1993). Its effects can still be prolonged: in pigs, four IGF-1 variants including LR3 lowered blood sugar 2 to 3 times more potently than IGF-1 and for much longer, and a truncated variant did the same in marmoset monkeys (Tomas et al., Journal of Endocrinology, 1997). So "longer-acting" is fair for the sugar-lowering effect, but not for how long it circulates.

Its designed job is in the lab. In serum-free Chinese hamster ovary cell cultures, LongR3 sustained cell viability better than insulin under production conditions (Morris and Schmid, Biotechnology Progress, 2000). When analysts found a long R3 IGF-I with a purification tag still attached in a black-market vial, they noted that this tagged form is usually produced for biochemical studies (Kohler et al., Growth Hormone & IGF Research, 2010).

How it differs from the approved drug, mecasermin

IGF-1 itself is an approved drug. Mecasermin (Increlex) is recombinant human IGF-1 whose sequence is identical to the natural hormone, and its US label covers growth failure in children 2 and older with severe primary IGF-1 deficiency, or with a growth hormone gene deletion and neutralizing antibodies to growth hormone. The label states it is not a substitute for growth hormone and is not for growth promotion once growth plates have closed (Increlex label, DailyMed).

IGF-1 LR3 is not mecasermin. It is a different molecule, and a 2021 doping-control paper notes that LR3 and related analogs were never approved for use in humans (Mongongu et al., Drug Testing and Analysis, 2021). We found no description of its effects in people. The reason to read mecasermin's label anyway is that it is the closest human safety record for IGF-1 biology, and the label is blunt, as covered below.

What people use it for

What the research actually shows

No human studies

We searched PubMed and ClinicalTrials.gov and found no human trial of IGF-1 LR3 and no ClinicalTrials.gov record for it. Everything below is animal or cell work.

Muscle: mixed, and mostly not muscle

The best case for muscle is in rats made catabolic with a steroid. Native IGF-1 and LR3 partly reversed the weight loss and protein breakdown, and LR3 was about 2.5 times as potent as IGF-1. But the IGF peptides also grew the gut, by up to 45%, and the gain in carcass weight reflected nitrogen rather than fat (Tomas et al., 1992). In later work by the same group, LR3 remained more potent for weight gain and organ weights, yet was "barely equipotent" with IGF-1 for reversing carcass muscle loss (Tomas et al., Journal of Endocrinology, 1996).

The clearest negative result came from food-restricted rats. LR3 helped them hold on to body weight and nitrogen, but muscle protein was not conserved, and in adult rats it made muscle breakdown worse (Tomas, Growth Hormone & IGF Research, 2001). So the animal literature does not support the simple story that more IGF-1 activity means more muscle.

Other species: no clear growth, and organ growth

In pigs, a short LR3 infusion reduced weight gain and food intake and also lowered the animals' own growth hormone, IGF-I, IGFBP-3 and insulin, the opposite of what the bodybuilding pitch predicts (Dunaiski et al., Journal of Endocrinology, 1997). In guinea pigs, LR3 did not stimulate overall growth but did increase the relative weight of the adrenals, gut, kidneys and spleen, and lowered circulating IGF-I, IGF-II and binding proteins (Conlon et al., Journal of Endocrinology, 1995). In suckling rats, kidney and spleen weights rose by up to 85% and 76% and gut tissue grew, with LR3 more potent than IGF-1 (Steeb et al., American Journal of Physiology, 1997). Those are young or normal animals under lab conditions, but they show what IGF-1 analogs reliably do: they grow visceral organs, and they can suppress the body's own growth hormone axis.

Blood sugar

IGF-1 has insulin-like effects, and the modified versions push that further. In pigs, variants including LR3 lowered plasma glucose 2 to 3 times more potently than IGF-1 (a truncated variant did the same in marmosets), and across the two species the cumulative suppression over four hours was roughly 4 to 8 times greater. The authors even suggested the variants might be useful alongside insulin for high blood sugar (Tomas et al., 1997). For a person who is not being monitored, that is a risk, not a feature.

Everything else

We found no study of IGF-1 LR3 for fat loss, joint or tendon healing, recovery or anti-aging, in animals or people. Those claims are anecdotal.

Side effects and risks

With no human data, here is what the record supports.

• Low blood sugar. Mecasermin's label warns of severe hypoglycemia leading to seizures. In the trials behind it, 30 of 71 children (42%) had hypoglycemia at least once, 5 had severe episodes needing help, and 4 had seizures or loss of consciousness (Increlex label). The animal data say the modified analogs lower glucose more and for longer (Tomas et al., 1997).
• Cancer signals. The label says several cases of malignant neoplasia have been seen in children treated with mecasermin and contraindicates it in children with active or past malignancy. Separately, a meta-analysis of blood-level studies found higher circulating IGF-I associated with modestly higher risk of prostate cancer and premenopausal breast cancer (Renehan et al., Lancet, 2004). That is an association for natural IGF-I, not a test of LR3, and it does not prove cause; the honest statement is that nobody has studied LR3 for it.
• Other label warnings for IGF-1 therapy. Intracranial hypertension, enlarged tonsils and adenoids, hip problems in growing children, and worsening scoliosis (Increlex label). These are from a supervised pediatric drug, so they show what IGF-1 exposure can do, not what LR3 will do.
• Organ growth and axis suppression. Seen in animals, above. A 2026 clinical review of these unregulated growth-axis compounds, IGF-1 LR3 among them, lists dysglycaemia and "biologically plausible but unproven mitogenic concerns" among the class risks (Dominikowski et al., Frontiers in Endocrinology, 2026).
• Sport. IGF-1 and its analogs including LR3 are described as prohibited in sport in a doping-control paper, which also notes LR3 was never approved for human use (Mongongu et al., 2021).

There is also a documented quality problem. A vial sold as long R3 IGF-I turned out to contain a version carrying a six-histidine purification tag, whose effects in humans the analysts said had not been described (Kohler et al., 2010). A separate analytical study found abundant signs of lower-quality, oxidized peptide forms in black-market products of these analogs (Mongongu et al., 2021). Neither tells you how common such products are. Both say a vial's label is not proof of what is inside, and IGF-1 LR3 is a much larger molecule than most compounds we cover, so it is worth verifying.

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for IGF-1 LR3. That doesn't mean vials are good or bad; it means nobody has submitted a report we can count. If you have had an IGF-1 LR3 vial tested, submitting the report is the fastest way to change that.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, lean on the general checks. Look at each vendor's full record and how many reports sit behind the score, and treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). Given the tagged and oxidized products described above, an independent identity and purity test on your own vial matters more here than for most compounds; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Buyers researching IGF-1 LR3 often also look at PEG-MGF, tesamorelin and CJC-1295, which work on the growth hormone axis rather than replacing IGF-1 directly. Our peptide hub lists every compound we track, and what are grey market peptides explains the market itself.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; IGF-1 LR3 is sold for research use only, has never been approved for human use, and has no human trial that we could find.